Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|November 1, 2022
Terumo Pharmaceutical Solutions Expands CDMO Services
Author(s)Pharmaceutical Technology Editors
The company is expanding its contract development and manufacturing services for parenteral drugs to global customers.
Advertisement
Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation, announced on Oct. 31, 2022 that it is expanding its contract development and manufacturing services for parenteral drugs to customers outside of Japan. The contract and development manufacturing organization (CDMO) offers end-to-end services with pre-filled syringe (PFS) design, molding, drug preparation, filling, assembly, and final packaging for biotech drugs and small molecules.
The expanded services would include early development stage to large-scale commercial production for global pharmaceutical customers, including assembly of PFS with devices such as autoinjectors and needle safety devices. The company would also offer customers global regulatory submissions support.
“I am excited for what the future holds for Terumo as we are in a unique position being able to offer an integrated solution of primary container, fill and finish capability, and device assembly, in addition to our traditional offering of injection, primary container, and infusion therapy devices,” said Marco Chiadò Piat, president of Terumo Pharmaceutical Solutions, in a press release.
Terumo will be showcasing the new global CDMO service at CPHI Frankfurt from Nov. 1–3, 2022.
Source:
Advertisement
Related to this article
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
Advertisement
Advertisement